NCT00609895已完成4 期
The Incidence of Hypoglycemia in Insulin Glargine-Treated Subjects With Diabetes Mellitus Upon Switching Between Bedtime and Morning Dosing
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 22
- 试验地点
- 1
- 主要终点
- Compare % of subjects with glucose > or = to 56 mg/dL at any point of 8-point glucose profiles during 3 consecutive days
研究概览
简要总结
To compare the percentage of subjects with a glucose measurement < than or = to 56 mg/dL at any point of the 8-point glucose profiles during 3 consecutive days before vs. 3 consecutive days after switching insulin glargine dosing time from bedtime to morning and vs. 3 consecutive days after switching back to bedtime dosing of insulin glargine.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 6 Years 至 75 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Type 1 or type 2 diabetes mellitus diagnosis for at least 1 year Administration of insulin glargine for at least 2 months prior to screening; subjects must be on a stable dose of insulin glargine, + or - 15%, for at least 1 week prior to screening, given once daily at bedtime, and the dose must remain unchanged (+ or - 15%) during the screening period.
- •If subjects are taking a short-acting insulin (e.g., regular human insulin, insulin lispro, or insulin aspart) or oral antidiabetic agents (e.g., a sulfonylurea, metformin, an alpha-glucosidase inhibitor, a thiazolidinedione, or a metiglinide), the subject must have been receiving these medications for at least 2 months prior to screening.
- •For subjects taking an oral antidiabetic agent, the dose must be unchanged for the 2 weeks (4 weeks for a thiazolidinedione) prior to screening and should not be expected to be changed from the screening visit (day 14) through the final visit (day 11). The dose of any short-acting insulin may be changed if medically indicated.
- •Males or non-pregnant females between the ages of 6 and 75 years; women must be postmenopausal for more than 2 years, surgically sterile, or agree to use a reliable contraceptive measure for the duration of the study. Reliable contraceptive measures include the following: systemic contraceptive (oral, implant, injections), diaphragm with intravaginal spermicide, cervical cap, intrauterine device, or condom with spermicide.
- •Ability and willingness to perform blood glucose profiles using a plasma glucose meter provided at home over 11 consecutive days.
- •HbA1c < than or = to 8.5% at screening.
排除标准
- •Use of any other intermediate- or long-acting insulin (e.g., NPH, Ultralenter, Lenter) within the last 2 months prior to screening.
- •Likelihood of requiring treatment during the study period with drugs not permitted by the study protocol (e.g., systemic corticosteroids).
- •History of hypoglycemia unawareness.
- •Pregnancy (as determined by a serum pregnancy test at the screening visit).
- •Breast-feeding.
- •Treatment with any investigational drug in the 2 months prior to the screening visit.
- •Clinically relevant cardiovascular, hepatic, neurologic, endocrine, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult.
- •History of drug or alcohol abuse.
- •Impaired hepatic function, as shown by but not limited to serum glutamic-oxaloacetic transaminase (SGPT, also known as alanine transaminase [ALT]) or serum glutamic-pyruvic transaminase (SGOT, also known as aspartate transaminase [AST]) above 2x the upper limit of normal range (ULN) measured at the screening visit.
- •Impaired renal function, as shown by, but not limited to serum creatinine > than or = to 1.5 mg/dL (133 micromol/L) [males] or > than or = to1.4 mg/dL (124 micromol/L) [females] measured at the screening visit. Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study. Subject unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study.
- •Subjects who work the night shift.
结局指标
主要结局
Compare % of subjects with glucose > or = to 56 mg/dL at any point of 8-point glucose profiles during 3 consecutive days
时间窗: before vs. after switching dosing time from bedtime to morning and vs. after switching back to bedtime
次要结局
- To compare the changes from baseline in glucose values at each specific measurement time of the 8-point glucose profile during 3 consecutive days(before vs. after switching dosing time from bedtime to morning and vs. after switching back to bedtime)
- To compare the mean daily rate of hypoglycemia during 3 consecutive days(before vs. after switching dosing time from bedtime to morning and vs. after switching back to bedtime)
- Compare % subjects with glucose measurements < or = to 72 mg/dL & < or = to 36 mg/dL at any point of the 8-point glucose profile during 3 consecutive days(before vs. after switching dosing time from bedtime to morning and vs. after switching back to bedtime)
- To compare the incidence of symptomatic hypoglycemia(at any time during 3 consecutive days before vs. after switching dosing time from bedtime to morning and vs. after switching back to bedtime)
- To evaluate overall safety and tolerability based on adverse event reporting, laboratory tests, and clinical examinations(at any time during the study)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A Survey on Low Blod Sugar Among Insulin-treated Patients With DiabetesDiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2NCT02306681Novo Nordisk A/S7,315
Unknown
不适用
Hypoglycemia at Initiation of Pump Therapy in Children With Type 1 DiabetesType 1 DiabetesNCT01840358St. Justine's Hospital30
撤回
不适用
Blood Sugars in Children With Idiopathic Seizures.SeizuresHypoglycemiaHyperammonemiaNCT00279851Children's Mercy Hospital Kansas City
已完成
不适用
Abnormal Post-partum Glucose Metabolism After Gestational Diabetes Diagnosed Before or After 24 Weeks of GestationGestational DiabetesGlucose IntoleranceType 2 DiabetesNCT01839448Centre Hospitalier Universitaire de Nīmes500
已完成
4 期
Phase 4 Study in the Elderly Patients With T2DMElderlyType 2 Diabetes MellitusNCT01238978Novartis46